PDF herunterladen
Exp Clin Endocrinol Diabetes 2018; 126(08): 478-486
DOI: 10.1055/s-0043-119076
Article
© Georg Thieme Verlag KG Stuttgart · New York

Effect of Diabetes on the Assessment Role of 2-Oxoglutarate to the Severity of Chronic Heart Failure

Pingan Chen
1   Department of Cardiology, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, China
,
Lina Hou
2   Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China
,
Yishan Luo
1   Department of Cardiology, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, China
,
Lushan Chen
1   Department of Cardiology, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, China
,
Shaonan Li
1   Department of Cardiology, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, China
,
Xiaoming Lei
1   Department of Cardiology, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, China
,
Jiankai Huang
1   Department of Cardiology, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, China
,
Daihong Wu
3   Ultrasonic Department, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, China
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 18. Mai 2017
revised 03. August 2017

accepted 30. August 2017

Publikationsdatum:
08. November 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Background Serum 2-oxoglutarate can reflect the severity of chronic heart failure (CHF) in patients without diabetes. Whether this predictive role persists in type 2 diabetes mellitus (T2DM) patients is unclear. In this study, we investigated this predictive role in T2DM patients and whether 2-oxoglutarate can indicate the diastolic or systolic function of left ventricle.

Methods One hundred eighty CHF patients (76 with T2DM) and 66 healthy controls were studied. 2-Oxoglutarate was assayed by liquid chromatography-mass spectrometry/mass spectrometry. Echocardiographic parameters, N-terminal pro-B-type natriuretic peptide (NT-proBNP) and other parameters were measured.

Results 2-Oxoglutarate was increased in CHF patients with or without T2DM compared with controls (both P<0.01). Patients with a lower left ventricular ejection fraction or a higher NT-proBNP or left ventricular end-diastolic volume index had higher levels of 2-oxoglutarate (median, 18.77 μg/mL versus 11.25 μg/mL; median, 14.06 µg/ml versus 9.39 µg/ml; median, 18.06 µg/mL versus 11.60 µg/mL, all P<0.05) in nondiabetic patients but not in T2DM patients. In multiple logistic regression analysis, NT-proBNP (OR=3.445, 95% CI=1.098 to 10.816, P=0.034) and left ventricular end-diastolic diameter (OR=2.544, 95% CI=1.033 to 6.268, P=0.042) were independently associated with increased 2-oxoglutarate in nondiabetic patients.

Conclusions The levels of 2-oxoglutarate can reflect the clinical severity of CHF in nondiabetic patients but not in those with T2DM, and it can be used as a potential indicator of the systolic dysfunction of the left ventricle.

 

  • References

  • 1 Kadkhodayan A, Coggan AR, Peterson LR. A "PET" area of interest: myocardial metabolism in human systolic heart failure. Heart Fail Rev 2013; 18: 567-574
    CrossrefPubMedGoogle Scholar
  • 2 Mori J, Basu R, McLean BA. et al. Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fraction. Circ Heart Fail 2012; 5: 493-503
    CrossrefPubMedGoogle Scholar
  • 3 Nasir S, Aguilar D. Congestive heart failure and diabetes mellitus: Balancing glycemic control with heart failure improvement. Am J Cardiol 2012; 110: 50B-57B
    CrossrefPubMedGoogle Scholar
  • 4 Aneja A, Tang WH, Bansilal S. et al. Diabetic cardiomyopathy: Insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 2008; 121: 748-757
    CrossrefPubMedGoogle Scholar
  • 5 Liu JE, Palmieri V, Roman MJ. et al. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: The Strong Heart Study. J Am Coll Cardiol 2001; 37: 1943-1949
    CrossrefPubMedGoogle Scholar
  • 6 Vasu S, Morgan TM, Kitzman DW. et al. Abnormal stress-related measures of arterial stiffness in middle-aged and elderly men and women with impaired fasting glucose at risk for a first episode of symptomatic heart failure. J Am Heart Assoc 2015; 4: e000991
    CrossrefPubMedGoogle Scholar
  • 7 From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol 2010; 55: 300-305
    CrossrefPubMedGoogle Scholar
  • 8 Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure–abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004; 350: 1953-1959
    CrossrefPubMedGoogle Scholar
  • 9 Dunn WB, Broadhurst DI, Deepak SM. et al. Serum metabolomics reveals many novel metabolic markers of heart failure, including pseudouridine and 2-oxoglutarate. Metabolomics 2007; 3: 413-426
    CrossrefPubMedGoogle Scholar
  • 10 Samara MA, Tang WH, Cikach Jr F. et al. Single exhaled breath metabolomic analysis identifies unique breathprint in patients with acute decompensated heart failure. J Am Coll Cardiol 2013; 61: 1463-1464
    CrossrefPubMedGoogle Scholar
  • 11 Chen PA, Xu ZH, Huang YL. et al. Increased serum 2-oxoglutarate associated with high myocardial energy expenditure and poor prognosis in chronic heart failure patients. Biochim Biophys Acta 2014; 1842: 2120-2125
    PubMedGoogle Scholar
  • 12 McKee PA, Castelli WP, McNamara PM. et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285: 1441-1446
    CrossrefPubMedGoogle Scholar
  • 13 Ma YC, Zuo L, Chen JH. et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: 2937-2944
    CrossrefPubMedGoogle Scholar
  • 14 Schiller NB, Shah PM, Crawford M. et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American society of echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-367
    CrossrefPubMedGoogle Scholar
  • 15 Devereux RB, Alonso DR, Lutas EM. et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458
    CrossrefPubMedGoogle Scholar
  • 16 Pallant J. SPSS survival manual: a step by step guide to data analysis using SPSS for windows (version 10). UK: Open University Press; 2001: 23-101
    Google Scholar
  • 17 Buchanan J, Mazumder PK, Hu P. et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005; 146: 5341-5349
    CrossrefPubMedGoogle Scholar
  • 18 Kato T, Niizuma S, Inuzuka Y. et al. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail 2010; 3: 420-430
    CrossrefPubMedGoogle Scholar
  • 19 Lopatin YM, Rosano GM, Fragasso G. et al. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. Int J Cardiol 2016; 203: 909-915
    CrossrefPubMedGoogle Scholar
  • 20 Fragasso G, Perseghin G, De Cobelli F. et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J. 2006; 27: 942-948
    CrossrefPubMedGoogle Scholar
  • 21 Neijssel OM, Tempest DW. The role of energy-spilling reactions in the growth of Klebsiella aerogenes NCTC 418 in aerobic chemostat culture. Arch Microbiol 1976; 110: 305-311
    CrossrefPubMedGoogle Scholar
  • 22 Weiss RG, Gerstenblith G, Bottomley PA. ATP flux through creatine kinase in the normal, stressed, and failing human heart. Proc Natl Acad Sci USA 2005; 102: 808-813
    CrossrefPubMedGoogle Scholar
  • 23 Phan TT, Abozguia K, Nallur Shivu G. et al. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol 2009; 54: 402-409
    CrossrefPubMedGoogle Scholar
  • 24 Senni M, Paulus WJ, Gavazzi A. et al. New strategies for heart failure with preserved ejection fraction: The importance of targeted therapies for heart failure phenotypes. Eur Heart J 2014; 35: 2797-2815
    CrossrefPubMedGoogle Scholar
  • 25 Hoenig MR, Bianchi C, Rosenzweig A. et al. The cardiac microvasculature in hypertension, cardiac hypertrophy and diastolic heart failure. Curr Vasc Pharmacol 2008; 6: 292-300
    CrossrefPubMedGoogle Scholar
  • 26 Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62: 263-271
    CrossrefPubMedGoogle Scholar
  • 27 Fonarow GC, Stough WG, Abraham WT. et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: A report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007; 50: 768-777
    CrossrefPubMedGoogle Scholar
  • 28 Mentz RJ, Kelly JP, von Lueder TG. et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 2014; 64: 2281-2293
    CrossrefPubMedGoogle Scholar
  • 29 Siddiqi N, Singh S, Beadle R. et al. Cardiac metabolism in hypertrophy and heart failure: Implications for therapy. Heart Fail Rev 2013; 18: 595-606
    CrossrefPubMedGoogle Scholar
  • 30 Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004; 25: 634-641
    CrossrefPubMedGoogle Scholar
  • 31 Fukushima A, Lopaschuk GD. Cardiac fatty acid oxidation in heart failure associated with obesity and diabetes. Biochim Biophys Acta. 2016; 1860: 1525-1534
    PubMedGoogle Scholar
  • 32 Ménard SL, Croteau E, Sarrhini O. et al. Abnormal in vivo myocardial energy substrate uptake in diet-induced type 2 diabetic cardiomyopathy in rats. Am J Physiol Endocrinol Metab 2010; 298: E1049-E1057
    CrossrefPubMedGoogle Scholar
  • 33 Sonenshein AL. Control of key metabolic intersections in Bacillus subtilis. Nat Rev Microbiol 2007; 5: 917-927
    CrossrefPubMedGoogle Scholar
  • 34 Snaith CD, Wright G, Lofkin M. The effects of aspartate and 2-oxoglutarate upon glycolytic energy metabolites and mechanical recovery following global ischaemia in isolated rat hearts. J Mol Cell Cardiol 1992; 24: 305-315
    CrossrefPubMedGoogle Scholar
  • 35 Patel SG, Hsu JW, Jahoor F. et al. Pathogenesis of A−β+ ketosis-prone diabetes. Diabetes 2013; 62: 912-922
    CrossrefPubMedGoogle Scholar
  • 36 Fillmore N, Mori J, Lopaschuk GD. Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. Br J Pharmacol 2014; 171: 2080-2090
    CrossrefPubMedGoogle Scholar